Ultragenyx Pharmaceutical Inc (FRA:UP0)
€ 46.2 -0.4 (-0.86%) Market Cap: 4.31 Bil Enterprise Value: 3.76 Bil PE Ratio: 0 PB Ratio: 13.42 GF Score: 81/100

Ultragenyx Pharmaceutical Inc at Piper Sandler Healthcare Conference Transcript

Nov 29, 2022 / 03:00PM GMT
Release Date Price: €34.2
Christopher Joseph Raymond;Emil D. Kakkis
Piper Sandler & Co., Research Division - MD & Senior Research Analyst;Ultragenyx Pharmaceutical

Okay. We're going to go ahead and get started. Thanks, everybody, for being here, and thanks for attending. This is the 34th Annual Piper Sandler Healthcare Conference. My name is Chris Raymond. I'm one of the lead -- Biotech leads here on the research side at Piper. Very pleased to have with us Emil Kakkis who is the CEO -- President and CEO of Ultragenyx. Just to go over the format here, this is a fireside chat format, so very informal. So if anybody has any questions from the audience, please raise your hand, I'd love to get some participation in here for you guys. I have probably 3 hours of questions for Emil, but we only have about 20 minutes. So we're going to try to pack as much as we can in here.

But before we do that, Emil, maybe just provide for folks who might not -- for the rare investor who doesn't know Ultragenyx, maybe just give us a sort of a 2- to 3-minute overview of the company and then we'll jump in.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot